DermaStream™ Phase-1

DermaStream™ Phase-1 is the first treatment to apply a continuously fresh supply of bio-active debridement agents to a controlled chronic wound environment. DermaStream™ Phase-1 overcomes traditional limitations of enzymatic ointments including their short active period which rapidly diffuses efficacy upon application. Specially designed for DermaStream’s proprietary CST™ (Continuous Streaming Therapy) treatment, DermaStream™ Phase-1 delivers its ongoing fresh supply of active proteolytic enzymatic agents while continuously draining used solution, necrotic tissue and fibrin. This highly controlled, optimally receptive wound environment minimizes wound regression and accelerates healing time from months to weeks.

• Breaks down and proactively removes necrotic tissue and fibrin
• Controls an optimally moist and receptive biochemical state of the entire wound environment
• Irrigates a continuous, uniform flow of fresh enzymatic agents over entire wound surface
• Prepares the wound bed for regeneration

DermaStream™ Phase-1 enzymatic debridement benefits:

• Expedites debridement process from months to weeks
• In some cases the only, treatment for hard-to-heal chronic wound debridement
• Safe and selective removal of necrotic tissue & fibrin
• Can prevent surgery, amputation and other systemic complications
• Avoids hospitalization and clinic treatments
• Eliminates need for frequent wound redressing
• Suitable for hospital, out-patient and home use
• Painless and soothing
• The closed circuit system avoids cross-infection between patients caused by exposure and distribution of pathogenic bacteria
• Low cost - disposable and maintenance free

Additional benefits for nurses

Additional benefits for patients

• Highly effective, in some cases the only, treatment for hard-to-heal chronic wounds
• Touch-free wound care
• Unaided continuous streaming of continuously active debridement solution
• Transparent device for wound examination without dressing removal